Dr. Rule on the Role of BTK Inhibitors in MCL

Simon Rule, MD, PhD
Published: Tuesday, Sep 18, 2018



Simon Rule, MD, PhD, professor of hematology, Plymouth University Medical School, United Kingdom, discusses the role of BTK inhibitors in the treatment of patients with mantle cell lymphoma (MCL).

The rise of the BTK inhibitors ibrutinib (Imbruvica) and acalabrutinib (Calquence) have made the biggest impact on this disease, Rule says. A big unanswered question is whether the younger patient population needs these agents in the frontline setting. Data show these patients typically do well with high-dose cytarabine-based chemotherapy and then are off drugs with a standard quality of life. In the relapsed setting is where novel therapies are usually introduced.

Rule says there is an ongoing trial in Europe looking at high-dose cytarabine with 3 arms: chemotherapy, followed by stem cell transplant and maintenance therapy, plus 2 experimental arms incorporating ibrutinib, and seeing whether transplant can be avoided. This trial will likely take years to meet its accrual goal, but it will eventually challenge the traditional paradigm involving stem cell transplant. Rule concludes that it’s important to not to forget that chemotherapy is effective.


Simon Rule, MD, PhD, professor of hematology, Plymouth University Medical School, United Kingdom, discusses the role of BTK inhibitors in the treatment of patients with mantle cell lymphoma (MCL).

The rise of the BTK inhibitors ibrutinib (Imbruvica) and acalabrutinib (Calquence) have made the biggest impact on this disease, Rule says. A big unanswered question is whether the younger patient population needs these agents in the frontline setting. Data show these patients typically do well with high-dose cytarabine-based chemotherapy and then are off drugs with a standard quality of life. In the relapsed setting is where novel therapies are usually introduced.

Rule says there is an ongoing trial in Europe looking at high-dose cytarabine with 3 arms: chemotherapy, followed by stem cell transplant and maintenance therapy, plus 2 experimental arms incorporating ibrutinib, and seeing whether transplant can be avoided. This trial will likely take years to meet its accrual goal, but it will eventually challenge the traditional paradigm involving stem cell transplant. Rule concludes that it’s important to not to forget that chemotherapy is effective.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Moving Forward From the Status Quo for the Treatment of Soft Tissue Sarcoma: Key Questions and New Answers to Optimize OutcomesOct 31, 20182.0
Hematology Briefings™: Advancing Care and Improving Outcomes for Patients With Pyruvate Kinase DeficiencyOct 31, 20181.0
Publication Bottom Border
Border Publication
x